Replacing Triton™ X‑100 Without Compromise: Meet Virodex™

If you were at BioProcess International Europe this year, you may have caught a glimpse of us talking about detergent alternatives for viral inactivation. If you weren’t, or if you’ve since heard the name Virodex™ and wanted to know what sits behind it, this is for you. 

While replacing Triton™ X‑100 has become a necessity, not all alternatives are designed for the realities of modern bioprocessing. With Virodex™, we focused on delivering a REACH‑compliant, compendial‑grade solution backed by data that stands up in real processes. 

Why replacing Triton™ X‑100 isn’t a simple swap 

Triton™ X‑100 has long been trusted for viral inactivation and cell lysis in biopharmaceutical manufacturing. Its performance was never the issue, but its inclusion on the REACH authority list and subsequent European ban changed the landscape, pushing manufacturers to reassess established workflows. 

Replacing Triton™ X‑100 is only useful if the alternative delivers equivalent performance, integrates cleanly downstream, and doesn’t introduce additional regulatory or process risk. 

That challenge is exactly what Virodex™ TXR‑1 and Virodex™ TXR‑2 were developed to address. 

Proven viral inactivation, supported by robust data 

Both Virodex™ TXR‑1 and Virodex™ TXR‑2 are non‑ionic surfactants designed specifically for viral inactivation and cell lysis in biopharmaceutical processes.  

• In head-to-head testing using xenotropic murine leukaemia virus (XMuLV) as a model lipid‑enveloped virus, they demonstrated equivalent virus inactivation performance to Triton™ X‑100 at the same use concentrations.
• Kinetic studies tell a more practical story. Across a range of temperatures relevant to bioprocessing, Virodex™ achieved rapid viral clearance, reaching accepted industry targets within short contact times. In several comparisons, performance exceeded that of other Triton™ X‑100 replacements evaluated under the same conditions. 

These results are about predictable, reproducible viral inactivation where consistency matters. 

Efective cell lysis across systems 

Virodex™ TXR‑1 and TXR‑2 both demonstrated effective mammalian cell lysis across industrially relevant cell lines, as well as strong performance in E. coli lysis, supporting their use in microbial and mammalian expression systems alike. 

Protein compatibility 

Maintaining protein integrity during detergent treatment is critical. As non‑ionic surfactants, both Virodex™ products showed excellent protein compatibility, with no loss of enzyme activity observed under relevant conditions, in line with expectations for detergents used in sensitive biologics manufacturing. 

Lower endotoxin levels, without trade‑offs 

Endotoxin control remains a key challenge, particularly for processes relying on E. coli. In comparative studies during plasmid DNA purification, use of Virodex™ TXR‑1 and TXR‑2 resulted in lower endotoxin levels than the other detergents evaluated, without impacting DNA yield or quality. 

Designed to fit into existing workflows 

Beyond upstream performance, Virodex™ was developed with downstream practicality in mind: 

• Effectively removed during Protein A chromatography, supporting use in monoclonal antibody manufacture 
• Detectable at low ppb levels using established analytical methods, aiding quality control
• Manufactured to cGMP EXCiPACT standards, with additional COA testing to support use in sterile manufacture 

TXR‑1 and TXR‑2 share a common purpose but offer flexibility depending on process needs, allowing teams to select the most appropriate option without compromising viral clearance performance.

Part of a broader bioprocessing toolkit 

Virodex™ sits within Croda Pharma’s wider bioprocessing portfolio, designed to support manufacturers across the production lifecycle, from high‑purity excipients and Super Refined™ materials to BioXPro™ amino acids for sensitive biological systems. 

Let’s continue the conversation 

If you didn’t get the chance to speak with us at BPI Europe, we’d be happy to talk through the Virodex™ data, discuss where TXR‑1 or TXR‑2 might fit within your process, or explore how they compare with what you’re using today. 

Replacing Triton™ X‑100 doesn’t have to mean compromise – and with Virodex™, it doesn’t. 

Triton is a trademark of The Dow Chemical Company or an affiliated company of Dow.